Total Payments
$660.07
2024 Payments
$288.50
Companies
18
Transactions
33
Medicare Patients
8,276
Medicare Billing
$5.6M

Payment Breakdown by Category

Food & Beverage$648.15 (98.2%)
Education$11.92 (1.8%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $648.15 32 98.2%
Education $11.92 1 1.8%

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $91.08 4 $0 (2024)
Novartis Pharmaceuticals Corporation $79.68 4 $0 (2020)
Celgene Corporation $62.51 3 $0 (2024)
ABBVIE INC. $60.40 2 $0 (2024)
Amgen Inc. $46.35 2 $0 (2023)
SERVIER PHARMACEUTICALS LLC $38.34 2 $0 (2024)
Lilly USA, LLC $36.75 2 $0 (2019)
Janssen Biotech, Inc. $35.19 2 $0 (2019)
Invivyd Inc $35.07 1 $0 (2024)
E.R. Squibb & Sons, L.L.C. $30.77 2 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $288.50 12 PFIZER INC. ($73.14)
2023 $46.35 2 Amgen Inc. ($46.35)
2022 $15.71 1 E.R. Squibb & Sons, L.L.C. ($15.71)
2021 $11.92 1 Gilead Sciences, Inc. ($11.92)
2020 $54.65 3 Novartis Pharmaceuticals Corporation ($22.50)
2019 $226.66 13 Novartis Pharmaceuticals Corporation ($57.18)
2018 $16.28 1 Genentech USA, Inc. ($16.28)

All Payment Transactions

33 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
11/05/2024 Celgene Corporation Food and Beverage Cash or cash equivalent $20.49 General
10/09/2024 PFIZER INC. IBRANCE (Drug), TUKYSA Food and Beverage In-kind items and services $25.01 General
Category: ONCOLOGY
10/08/2024 ABBVIE INC. ELAHERE (Drug) Food and Beverage In-kind items and services $32.27 General
Category: ONCOLOGY
09/26/2024 Invivyd Inc PEMGARDA (Biological) Food and Beverage In-kind items and services $35.07 General
Category: INFECTIOUS DISEASE
09/26/2024 SERVIER PHARMACEUTICALS LLC Voranigo (Drug) Food and Beverage In-kind items and services $19.57 General
Category: Oncology
08/22/2024 SERVIER PHARMACEUTICALS LLC Tibsovo (Drug) Food and Beverage In-kind items and services $18.77 General
Category: Oncology
08/14/2024 Celgene Corporation REBLOZYL (Biological) Food and Beverage Cash or cash equivalent $21.23 General
Category: Hematology
06/19/2024 Boston Scientific Corporation Food and Beverage In-kind items and services $19.04 General
Category: General - Therapies_CRM
05/14/2024 Celgene Corporation REBLOZYL (Biological) Food and Beverage Cash or cash equivalent $20.79 General
Category: Hematology
04/15/2024 PFIZER INC. TUKYSA (Drug) Food and Beverage In-kind items and services $27.47 General
Category: Oncology
04/09/2024 PFIZER INC. OXBRYTA (Drug) Food and Beverage In-kind items and services $20.66 General
Category: HEMATOLOGY
03/19/2024 ABBVIE INC. ELAHERE (Drug) Food and Beverage In-kind items and services $28.13 General
Category: ONCOLOGY
04/12/2023 Amgen Inc. Blincyto (Biological), Kyprolis Food and Beverage In-kind items and services $27.68 General
Category: Oncology
03/30/2023 Amgen Inc. Blincyto (Biological), Kyprolis Food and Beverage In-kind items and services $18.67 General
Category: Oncology
03/21/2022 E.R. Squibb & Sons, L.L.C. ELIQUIS (Drug) Food and Beverage Cash or cash equivalent $15.71 General
Category: Cardiovascular
06/01/2021 Gilead Sciences, Inc. Education In-kind items and services $11.92 General
02/20/2020 GlaxoSmithKline, LLC. ZEJULA (Drug) Food and Beverage In-kind items and services $15.02 General
Category: ONCOLOGY
01/23/2020 Novartis Pharmaceuticals Corporation PROMACTA (Drug), TASIGNA Food and Beverage In-kind items and services $22.50 General
Category: ONCOLOGY
01/08/2020 Eisai Inc. Lenvima (Drug) Food and Beverage Cash or cash equivalent $17.13 General
Category: Oncology
11/06/2019 Merck Sharp & Dohme Corporation LYNPARZA (Biological) Food and Beverage In-kind items and services $12.65 General
Category: ONCOLOGY
10/25/2019 Lilly USA, LLC VERZENIO (Drug) Food and Beverage In-kind items and services $16.13 General
Category: Oncology
10/18/2019 Novartis Pharmaceuticals Corporation Food and Beverage In-kind items and services $14.94 General
09/19/2019 Janssen Biotech, Inc. DARZALEX (Biological), IMBRUVICA Food and Beverage In-kind items and services $14.21 General
Category: Oncology
08/19/2019 Gilead Sciences, Inc. Food and Beverage In-kind items and services $13.70 General
07/10/2019 Seattle Genetics, Inc. ADCETRIS (Biological) Food and Beverage In-kind items and services $14.81 General
Category: Oncology

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 53 2,341 77,264 $6.9M $1.9M
2022 55 2,571 100,266 $7.1M $1.7M
2021 51 2,230 85,242 $5.9M $1.5M
2020 23 1,134 16,870 $1.1M $458,393
Total Patients
8,276
Total Services
279,642
Medicare Billing
$5.6M
Procedure Codes
188

All Medicare Procedures & Services

188 procedure records from CMS Medicare Utilization — Page 3 of 8

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
J1626 Injection, granisetron hydrochloride, 100 mcg Office 2023 16 470 $11,750 $141.55 1.2%
J1200 Injection, diphenhydramine hcl, up to 50 mg Office 2023 22 52 $208.00 $44.44 21.4%
J3490 Unclassified drugs Office 2023 15 34 $315.00 $21.32 6.8%
J9271 Injection, pembrolizumab, 1 mg Office 2022 28 26,400 $3.3M $1.1M 33.5%
Q5120 Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg Office 2022 20 900 $794,700 $121,136 15.2%
Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg Office 2022 14 4,174 $784,712 $120,642 15.4%
96413 Administration of chemotherapy into vein, 1 hour or less Office 2022 135 565 $387,590 $66,146 17.1%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 295 810 $147,852 $58,143 39.3%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 159 326 $82,816 $33,741 40.7%
J0185 Injection, aprepitant, 1 mg Office 2022 41 21,060 $189,540 $28,497 15.0%
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Office 2022 25 21,930 $109,650 $15,632 14.3%
96417 Administration of additional new drug or substance into vein, 1 hour or less Office 2022 45 182 $60,788 $10,582 17.4%
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) Office 2022 17 4,035 $84,735 $10,133 12.0%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2022 57 57 $29,808 $9,997 33.5%
96416 Administration of prolonged chemotherapy into vein Office 2022 16 83 $61,088 $9,902 16.2%
80053 Blood test, comprehensive group of blood chemicals Office 2022 207 928 $57,536 $9,631 16.7%
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less Office 2022 77 374 $56,848 $9,617 16.9%
96375 Injection of additional new drug or substance into vein Office 2022 80 605 $63,525 $8,255 13.0%
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count Office 2022 225 1,064 $37,240 $8,108 21.8%
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less Office 2022 59 89 $27,056 $5,084 18.8%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 32 39 $17,745 $5,005 28.2%
96411 Administration of additional new drug or substance into vein using push technique Office 2022 22 100 $28,100 $4,999 17.8%
J0640 Injection, leucovorin calcium, per 50 mg Office 2022 15 1,476 $35,808 $4,838 13.5%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 32 32 $12,996 $4,384 33.7%
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle Office 2022 14 56 $11,480 $3,755 32.7%

About Dr. Adam Goldrich, MD

Dr. Adam Goldrich, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Annapolis, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2011. The National Provider Identifier (NPI) number assigned to this provider is 1912292517.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Goldrich, MD has received a total of $660.07 in payments from pharmaceutical and medical device companies, with $288.50 received in 2024. These payments were reported across 33 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($648.15).

As a Medicare-enrolled provider, Goldrich has provided services to 8,276 Medicare beneficiaries, totaling 279,642 services with total Medicare billing of $5.6M. Data is available for 4 years (2020–2023), covering 188 distinct procedure/service records.

Practice Information

Products in Payments

  • ELAHERE (Drug) $60.40
  • Blincyto (Biological) $46.35
  • REBLOZYL (Biological) $42.02
  • PROMACTA (Drug) $40.82
  • VERZENIO (Drug) $36.75
  • PEMGARDA (Biological) $35.07
  • ELIQUIS (Drug) $30.77
  • TUKYSA (Drug) $27.47
  • IBRANCE (Drug) $25.01
  • GILOTRIF (Drug) $23.38
  • IMBRUVICA (Drug) $20.98
  • OXBRYTA (Drug) $20.66
  • Voranigo (Drug) $19.57
  • Tibsovo (Drug) $18.77
  • CHANTIX (Drug) $17.94
  • Lenvima (Drug) $17.13
  • Avastin (Biological) $16.28
  • ZEJULA (Drug) $15.02
  • ADCETRIS (Biological) $14.81
  • DARZALEX (Biological) $14.21

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Annapolis